Emma C. Tallantyre

Heath Park Way
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

EQUITY-MS: evaluating the quality of investigation and treatment of multiple sclerosis using data from five specialist neurology centres in the UK-study protocol.

EQUITY-MS: evaluating the quality of investigation and treatment of multiple sclerosis using data from five specialist neurology centres in the UK-study protocol.

Journal: BMJ open

Published: September 03, 2026

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Journal: Health technology assessment (Winchester, England)

Published: August 11, 2026

Multiple Sclerosis and ethnicity in Wales: a SAIL Databank study.

Multiple Sclerosis and ethnicity in Wales: a SAIL Databank study.

Journal: International journal of population data science

Published: August 01, 2026

Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden.

Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden.

Journal: Acta neuropathologica

Published: June 16, 2026

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 31, 2026

Multi-arm multi-stage platform trials for neurological disease: accelerating progress.

Multi-arm multi-stage platform trials for neurological disease: accelerating progress.

Journal: Lancet (London, England)

Published: May 13, 2026

A framework for blood biomarker discovery in MS.

A framework for blood biomarker discovery in MS.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 30, 2026

Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.

Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.

Journal: Neurology

Published: March 06, 2026

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis.

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis.

Journal: Frontiers in immunology

Published: January 26, 2026

Non-invasive biomarkers for Neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis.

Non-invasive biomarkers for Neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis.

Journal: Journal of neuroimmunology

Published: January 03, 2026

MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology.

MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology.

Journal: European journal of neurology

Published: October 14, 2025

Genetic subtypes associated with multiple sclerosis severity and response to treatment.

Genetic subtypes associated with multiple sclerosis severity and response to treatment.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: August 05, 2025

Showing 1-12 of 92

Last Updated: 09/26/2026